Daily Cosmetic Research Analysis
Analyzed 6 papers and selected 3 impactful papers.
Summary
Analyzed 6 papers and selected 3 impactful articles.
Selected Articles
1. Therapeutic Potential of 3D-Printed Nifurtimox for Chagas Disease: Effects on Survival, Parasitemia Control and Immune Modulation.
In a murine T. cruzi model, 3D-printed nifurtimox improved parasitemia control, modulated inflammatory cytokines in cardiac and skeletal muscle, and at 100 mg/kg achieved complete parasite clearance and protection even under immunosuppression; benefits likely derive from improved dissolution and amorphization.
Impact: Demonstrates a formulation strategy (3D printing/amorphization) that markedly increases efficacy and safety of an existing antiparasitic drug, enabling lower effective doses and potential translation to improved Chagas therapies.
Clinical Implications: Supports development of 3D-printed nifurtimox formulations as candidates for clinical trials aiming to reduce dose-related toxicity and improve efficacy in Chagas disease; immediate clinical impact is preclinical, but justifies translational work.
Key Findings
- 3D nifurtimox (50 and 100 mg/kg) controlled blood parasitemia better than conventional nifurtimox in surviving mice.
- 3D nifurtimox 100 mg/kg achieved complete parasite clearance and sustained protection, even under immunosuppression.
- Improved efficacy correlated with enhanced dissolution/bioavailability due to amorphous solid-state conversion by 3D printing.
Methodological Strengths
- In vivo efficacy tested in survival and immunosuppression challenge models
- Comparative assessment versus conventional nifurtimox and pharmacotechnical characterization (amorphous state, dissolution)
Limitations
- Preclinical (murine) results may not translate directly to humans; safety and pharmacokinetics in humans unknown
- Abstract lacks detailed dosing regimen, sample sizes and statistical metrics in provided text
Future Directions: Perform GLP toxicology and pharmacokinetic studies, scale manufacturing for GMP 3D-printed formulations, and design early-phase clinical trials to test safety, PK and efficacy in patients with acute and chronic Chagas disease.
OBJECTIVE: The Trypanosoma cruzi immunopathology is sustained by a progressive inflammatory process triggered by parasite antigens, resulting in structural and functional changes in infected organs. Current etiological treatments of benznidazole and nifurtimox show limited efficacy and high toxicity, particularly during chronic infection stages. To address these limitations, a novel 3D printing formulation was applied to nifurtimox (3D nifurtimox) to improve its dissolution and reduce cytotoxicity. This study evaluated the therapeutic efficacy of 3D nifurtimox in experimental T. cruzi infection.
METHODS: Female Swiss mice were infected with 4 × 10
RESULTS: 3D nifurtimox at 50 and 100 mg/kg showed more efficacy in controlling blood parasites in mice surviving and regulating inflammatory cytokine patterns in cardiac and skeletal muscle tissues than conventional nifurtimox. In addition, 3D nifurtimox 100 mg/kg demonstrated complete parasite clearance and sustained protection even under immunosuppression. The improved efficacy is likely related to enhanced dissolution and bioavailability afforded by the 3D printing process, which transformed nifurtimox into an amorphous solid state.
CONCLUSION: 3D nifurtimox represents a promising new version of nifurtimox capable of being used in low doses with comparable or superior effects to benznidazole (100 mg/kg) and can be considered a promising tool for anti-T. cruzi therapies.
2. Risk factors for breast fibrosis and unfavorable cosmetic outcomes after breast conserving therapy in the contemporary treatment era: a systematic review.
A systematic review of 12 prospective studies (12,118 patients) identified consistent risk factors for fibrosis and poor cosmetic outcomes after BCT: older age, larger tumor size, re-resection, poor early cosmetic result, high boost dose and volume, dose homogeneity issues, whole breast dose, and adjuvant chemotherapy. Data on complex oncoplastic techniques and ultra-hypofractionation remain insufficient.
Impact: Synthesizes high-quality prospective evidence across >12,000 patients to identify modifiable treatment-related and patient-related predictors of fibrosis and cosmetic outcome, informing surgical and radiotherapy planning.
Clinical Implications: Encourages attention to dose homogeneity, boost dose/volume planning, and sequencing of chemotherapy/radiotherapy; supports considering chemotherapy before radiotherapy when both are required and highlights need for individualized surgical planning to minimize re-resection.
Key Findings
- From 12 prospective studies (12,118 patients), risk factors for fibrosis and poor cosmetic outcome include increasing age, larger tumor size, and re-resection.
- Treatment-related predictors include high boost dose, greater boost volume per 10 cc, poor dose homogeneity, higher whole-breast dose, and adjuvant chemotherapy.
- No specific new risk factors were identified for complex oncoplastic techniques or ultra-hypofractionated radiotherapy due to insufficient high-quality data.
Methodological Strengths
- Inclusion restricted to prospective studies with ≥100 patients and use of validated bias-assessment tools (QUIPS, Cochrane)
- Large cumulative sample size (12,118 patients) enhancing generalizability
Limitations
- Heterogeneity in surgical techniques, radiotherapy protocols and outcome measures across included studies limits pooled inference
- Insufficient high-quality data on complex oncoplastic surgery and ultra-hypofractionation prevents definitive conclusions in these subgroups
Future Directions: Large, multidisciplinary prospective studies with standardized cosmetic outcome metrics and long-term follow-up are needed, especially evaluating complex oncoplastic techniques and ultra-hypofractionated schedules.
BACKGROUND: This systematic review aimed to identify risk factors for fibrosis and unfavorable cosmetic outcomes after breast conserving therapy (BCT) for breast cancer in the light of contemporary oncoplastic surgery and 3D-radiotherapy techniques.
METHODS: The systematic literature search was carried out in Embase, Ovid Medline, Cochrane Central Register of Controlled Trials, and CINAHL. Studies published after 2005, reporting two or more risk factors for fibrosis or unfavorable cosmetic outcomes as primary outcomes were eligible for inclusion. Only prospective studies with 100 or more patients analyzed were included. The Quality In Prognosis Studies tool and Cochrane risk-of-bias tool were used to assess risk of bias. Patient, tumor, and treatment-related predictors were identified.
RESULTS: Twelve papers investigating 12.118 patients were identified. Risk factors for both the development of fibrosis and unfavorable cosmetic outcomes were increasing age, larger tumor size, re-resection, poor early cosmetic outcomes before the start of radiotherapy, high boost dose, boost volume per 10 cc, homogeneity-index, dose whole breast irradiation, and adjuvant chemotherapy. No specific risk factors in the setting of BCT with complex oncoplastic surgery techniques or ultra-hypo fractionated radiotherapy were identified in this review.
CONCLUSION: The risk factors identified in this review are largely similar to those found in 2D-radiotherapy studies; dose homogeneity was additionally identified. Administering chemotherapy before radiotherapy should be considered for patients requiring both treatments. However, the lack of sufficient high-quality data regarding BCT with (complex) oncoplastic surgery techniques and ultra-hypo fractionated radiotherapy schedules address the need for large, multidisciplinary prospective studies with long-term follow-up.
3. Comprehensive Facial Skin Rejuvenation With Long-Term Regular Intense Pulsed Light Therapy: A Real-World Study.
Retrospective real-world study of 236 patients receiving ≥6 IPL sessions showed significant objective improvement in erythema, pigmentation and wrinkle indices by VISIA and GAIS. Regular treatment intervals and greater total sessions strongly predicted better outcomes; Fitzpatrick type IV skin had lower response. No severe adverse events were reported.
Impact: Provides quantified, real-world objective evidence that long-term, regular IPL improves multiple skin aging domains and identifies actionable predictors (intervals, session number), informing practice patterns in cosmetic dermatology.
Clinical Implications: Supports scheduling regular IPL treatments with consistent intervals and adequate total sessions to maximize cumulative benefits; caution in darker phototypes (Fitzpatrick IV) due to lower response—consider dose/parameter adjustments and counseling.
Key Findings
- Significant reductions in erythema, pigmentation, and wrinkle indices after long-term regular IPL (p < 0.05).
- Regular treatment intervals (OR = 13.62) and higher total number of sessions (OR = 3.80) independently predicted good response.
- Fitzpatrick skin Type IV associated with markedly lower response (OR = 0.12); no severe adverse events reported.
Methodological Strengths
- Objective VISIA imaging metrics and GAIS used to quantify multiple skin outcome domains
- Multivariable logistic regression to identify independent predictors of response
Limitations
- Retrospective design with potential selection and information bias
- Single-center or heterogeneous practice settings not specified; external validity may be limited
Future Directions: Prospective, controlled studies comparing standardized IPL regimens and intervals across skin phototypes, with longer-term follow-up and stratified safety evaluation for darker skin types.
BACKGROUND: Intense pulsed light (IPL) therapy is widely used for facial rejuvenation, targeting vascular, pigmentary, and textural changes. However, comprehensive, real-world evidence evaluating long-term, regular IPL treatment across multiple dimensions of skin improvement remains limited. OBJECTIVES: This study aimed to assess the efficacy and safety of long-term, regular IPL therapy in improving facial erythema, pigmentation, and wrinkles, and to identify predictors of favorable response. METHODS: This retrospective real-world study included 236 patients who underwent six or more IPL sessions between 2020 and 2025. Patients were categorized as acne, rosacea, or cosmetic subjects. VISIA imaging quantified erythema, pigmentation, and wrinkle indices, while the Global Aesthetic Improvement Scale (GAIS) was used to assess aesthetic outcomes. Logistic regression identified predictors of good response. RESULTS: Significant improvements were observed in erythema, pigmentation, and wrinkle indices after treatment (all p < 0.05). Regular treatment intervals and total number of sessions were independently associated with better outcomes (OR = 13.62 and 3.80, respectively, both p < 0.05). Patients with Fitzpatrick Type IV skin showed lower response rates (OR = 0.12, p = 0.001). VISIA analyses demonstrated quantifiable reductions in erythema and pigmentation areas, while wrinkles showed notable textural improvement. No severe adverse events occurred. CONCLUSIONS: Long-term, regular IPL therapy effectively improves facial erythema, pigmentation, and wrinkles, confirming its value as a comprehensive rejuvenation strategy. Regular treatment intervals optimize cumulative effects, while objective imaging enhances precision in outcome evaluation. These findings support IPL as a safe, evidence-based, and multidimensional approach to long-term facial rejuvenation.